Malcolm A. Leissring, Ph.D.
Advisor/ Pharmaceutical and Medical Strategist
Dr. Malcolm A. Leissring is an award-winning biomedical researcher who is internationally recognized for his work on the molecular pathogenesis of Alzheimer’s disease and diabetes mellitus. He conducted his postdoctoral training at Harvard Medical School in the laboratory of Dennis J. Selkoe, M.D., the world’s leading researcher in Alzheimer’s disease. Dr. Leissring’s research has been funded by grants from the National Institutes of Health and numerous private foundations, and he has published more than 50 peer-reviewed articles in top-tier scientific journals.
Of note, Dr. Leissring pioneered the development of pharmacological inhibitors of insulin-degrading enzyme (IDE), which have demonstrated utility for the treatment of diabetes (Maianti et al., Nature 2014) and wound healing (Suire et al., PLoS ONE 2018). Dr. Leissring has received awards from many prestigious organizations, including the Alzheimer’s Association, the American Diabetes Association, the Ellison Medical Foundation, and the American Federation for Aging Research.
Dr. Leissring is currently working as an Associate Professor of Research at the University of California, Irvine’s Institute for Memory Impairments and Neurological Disorders (UCI MIND).
He is also the CEO/President of the Auguste Deter Foundation, a Nonprofit organization focused on Alzheimer’s disease prevention.
Dr. Malcolm Leissring studied at University of California, Berkeley for his A.B. (psychology). At the San Francisco State University, he received his M.A. (biology). His Ph.D. (neurobiology) was through the University of California, Irvine and led into his Post Doctorate at Harvard Medical School.
KRLT Biotech Inc